Phase 1 study of polyethylene glycol formulation of interferon α-2B (Schering 54031) in Philadelphia chromosome–positive chronic myelogenous leukemia

Pharmacokinetics

1982 • 3,815 citations

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1996 • 2,073 citations

Peginterferon Alfa-2a in Patients with Chronic Hepatitis C

2000 • 1,246 citations

Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis

2000 • 893 citations

Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia

1994 • 592 citations

Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia

1997 • 565 citations

Chronic Myelogenous Leukemia: Biology and Therapy

1999 • 483 citations

Biologic Therapy of Cancer

1992 • 476 citations

Chronic myelogenous leukemia: a concise update

1993 • 453 citations

Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-α Therapy

1995 • 446 citations

UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response

1995 • 409 citations

Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia

1991 • 398 citations

Comparative pharmacokinetic studies of three asparaginase preparations.

1993 • 328 citations

Chronic myelogenous leukemia in blast crisis

1987 • 283 citations

Interferon Alfa Versus Chemotherapy for Chronic Myeloid Leukemia: A Meta-analysis of Seven Randomized Trials

1997 • 282 citations

Characteristics of accelerated disease in chronic myelogenous leukemia

1988 • 280 citations

Recombinant Interferon Alfa-2b Combined with a Regimen Containing Doxorubicin in Patients with Advanced Follicular Lymphoma

1993 • 263 citations

Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity

2000 • 214 citations

Treatment of chronic myelogenous leukemia: current status and investigational options [see comments]

1996 • 192 citations

Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration

1988 • 184 citations

PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques.

1998 • 151 citations

Treatment of Philadelphia Chromosome-Positive Early Chronic Phase Chronic Myelogenous Leukemia With Daily Doses of Interferon Alpha and Low-Dose Cytarabine

1999 • 144 citations

Identification of the Major Positional Isomer of Pegylated Interferon Alpha-2b

2000 • 129 citations

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.

1992 • 117 citations

IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency.

1992 • 113 citations

Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies

1995 • 90 citations

Polyethylene Glycol Modification: Relevance of Improved Methodology to Tumour Targeting

1996 • 81 citations

Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin

2001 • 75 citations

Combined Interferon Alfa-2a and Cytosine Arabinoside as First-Line Treatment for Chronic Myeloid Leukemia

1993 • 56 citations

Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation

2000 • 51 citations

Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization

1990 • 42 citations

A highly sensitive electrochemiluminescence immunoassay for interferon alfa-2b in human serum

1997 • 35 citations

Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: Results of the austrian multicenter phase II study

1997 • 32 citations

EMOTIONAL FACTORS IN ORGANIC DISEASE

1949 • 6 citations

Deleted Work

1955 • 0 citations